{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:02:18Z","timestamp":1794283338921,"version":"4.9.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["2005-001"],"award-info":[{"award-number":["2005-001"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000042","name":"Amgen Foundation","doi-asserted-by":"publisher","award":["2005-002"],"award-info":[{"award-number":["2005-002"]}],"id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2005-003"],"award-info":[{"award-number":["2005-003"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01549-0","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:16:18Z","timestamp":1782260178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term follow-up of the transplant-eligible cohort of the EMN12\/HOVON-129 study for primary plasma cell leukemia patients"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-2603","authenticated-orcid":false,"given":"Niels W. C. J.","family":"van de Donk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0569","authenticated-orcid":false,"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-2671","authenticated-orcid":false,"given":"Bronno","family":"van der Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-8379","authenticated-orcid":false,"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Lung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"Broijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3976-8001","authenticated-orcid":false,"given":"Wilfried W. H.","family":"Roeloffzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gadisseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pietrantuono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludek","family":"Pour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9457-3763","authenticated-orcid":false,"given":"Vincent H. J.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3509-3780","authenticated-orcid":false,"given":"Thomas","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2749-7347","authenticated-orcid":false,"given":"Massimo","family":"Offidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4539-6363","authenticated-orcid":false,"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wida","family":"Razawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Silkjaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3175-1195","authenticated-orcid":false,"given":"Jo","family":"Caers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-6267","authenticated-orcid":false,"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2131-731X","authenticated-orcid":false,"given":"Annette Juul","family":"Vangsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-412X","authenticated-orcid":false,"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-2237","authenticated-orcid":false,"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3277-6594","authenticated-orcid":false,"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"1549_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00587-0","volume":"11","author":"C Fern\u00e1ndez de Larrea","year":"2021","unstructured":"Fern\u00e1ndez de Larrea C, Kyle R, Rosi\u00f1ol L, Paiva B, Engelhardt M, Usmani S, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11:192.","journal-title":"Blood Cancer J"},{"key":"1549_CR2","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1182\/blood-2012-05-408682","volume":"120","author":"NW van de Donk","year":"2012","unstructured":"van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG. How I treat plasma cell leukemia. Blood. 2012;120:2376\u201389.","journal-title":"Blood"},{"key":"1549_CR3","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1470-2045(23)00405-9","volume":"24","author":"N van de Donk","year":"2023","unstructured":"van de Donk N, Minnema MC, van der Holt B, Schjesvold F, Wu KL, Broijl A, et al. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12\/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. Lancet Oncol. 2023;24:1119\u201333.","journal-title":"Lancet Oncol"},{"key":"1549_CR4","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF, et al. International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025;43:2739\u201351.","journal-title":"J Clin Oncol"},{"key":"1549_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01355-0","volume":"15","author":"L Foster","year":"2025","unstructured":"Foster L, Anderson LD Jr., Chung A, Chaulagain CP, Pettijohn E, Cowan AJ, et al. Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses. Blood Cancer J. 2025;15:154.","journal-title":"Blood Cancer J"},{"key":"1549_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","volume":"124","author":"WI Gonsalves","year":"2014","unstructured":"Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014;124:907\u201312.","journal-title":"Blood"},{"key":"1549_CR7","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/leu.2011.312","volume":"26","author":"A Mahindra","year":"2012","unstructured":"Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia. 2012;26:1091\u20137.","journal-title":"Leukemia"},{"key":"1549_CR8","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","volume":"34","author":"B Royer","year":"2016","unstructured":"Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, et al. Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the intergroupe francophone du my\u00e9lome. J Clin Oncol. 2016;34:2125\u201332.","journal-title":"J Clin Oncol"},{"key":"1549_CR9","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1038\/s41375-020-0830-0","volume":"34","author":"B Dhakal","year":"2020","unstructured":"Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, et al. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2020;34:3338\u201347.","journal-title":"Leukemia"},{"key":"1549_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/leu.2013.241","volume":"28","author":"P Musto","year":"2014","unstructured":"Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014;28:222\u20135.","journal-title":"Leukemia"},{"key":"1549_CR11","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3324\/haematol.2021.280568","volume":"108","author":"S Lawless","year":"2023","unstructured":"Lawless S, Iacobelli S, Knelange NS, Chevallier P, Blaise D, Milpied N, et al. Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling. Haematologica. 2023;108:1105\u201314.","journal-title":"Haematologica"},{"key":"1549_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01442-2","volume":"15","author":"T Hellou","year":"2025","unstructured":"Hellou T, Kumar SK, Alouch SS, Almodovar-Diaz A, Dispenzieri A, Jevremovic D, et al. Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia. Blood Cancer J. 2025;15:215.","journal-title":"Blood Cancer J"},{"key":"1549_CR13","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1182\/blood.2021014968","volume":"139","author":"T Cazaubiel","year":"2022","unstructured":"Cazaubiel T, Leleu X, Perrot A, Manier S, Buisson L, Maheo S, et al. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features. Blood. 2022;139:2666\u201372.","journal-title":"Blood"},{"key":"1549_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0059-6","volume":"8","author":"E Katodritou","year":"2018","unstructured":"Katodritou E, Terpos E, Delimpasi S, Kotsopoulou M, Michalis E, Vadikolia C, et al. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer J. 2018;8:31.","journal-title":"Blood Cancer J"},{"key":"1549_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.annonc.2025.01.022","volume":"36","author":"P Musto","year":"2025","unstructured":"Musto P, Engelhardt M, van de Donk N, Gay F, Terpos E, Einsele H, et al. European Myeloma Network Group review and consensus statement on primary plasma cell leukemia. Ann Oncol : Off J Eur Soc Med Oncol. 2025;36:361\u201374.","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01549-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01549-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01549-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:16:19Z","timestamp":1782260179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01549-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1549"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01549-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NWCJvdD has received research support from Janssen Pharmaceuticals, AMGEN, Celgene, CellCentric, Novartis, Cellectis and BMS, and serves in advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Sanofi, Takeda, Roche, Novartis, Bayer, Adaptive, Galapagos, Kite Pharma, Merck, Pfizer, AbbVie, and Servier, all paid to institution; FS has received research support from Celgene, Janssen, Oncopeptides, Sanofi, GSK, and Targovax, and received honoraria from Amgen, BMS, Takeda, Abbvie, Janssen, Novartis, SkyliteDX, Oncopeptides, Sanofi, Pfizer, Daiki-Sankyo, GSK, and participated on a data safety monitoring board or advisory board for Abbvie, GSK, Celgene, Takeda, Janssen, Oncopeptides, Sanofi, BMS; BvdH has received honoraria for data safety monitoring board membership from Intergroupe Francophone du My\u00e9lome (IFM) and Heidelberg University Hospital; MCM has received research support from Beigene, has a consultancy or advisory role for Janssen, GSK, and CDR-life, and receives honoraria from BMS, Pfizer, Janssen, and Medscape, and serves on a data safety monitoring board for BMS; all paid to employer; KLW has served in advisory boards for Janssen and Pfizer; AB received honoraria and served in advisory boards from BMS, Janssen, Amgen, and Sanofi; WWHR received honoraria from Amgen and SANOFI, all paid to employer, and received support for travel from Takeda and Abbvie, and participated in advisory boards for BMS\/Celgene, Janssen, all paid to employer; AG none; GP none; LP none; VHJvdV reports a Laboratory Services Agreement with BD Biosciences, Cytognos and Agilent; all paid to employer; TL has received research grants from Takeda, AMGEN, and Janssen, and has received honoraria from AMGEN, Janssen, BMS, and Pfizer, and has received traveling support from Pfizer and Janssen, and has received equipment from Takeda and Pfizer; MO has received honoraria and served in advisory board for AbbVie, Amgen, BMS, GSK, Janssen, Sanofi, and Takeda; SB has received honoraria from Amgen, Celgene\/Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, and Abbvie, serves in scientific advisory boards for Celgene\/Bristol-Myers Squibb, Janssen, Takeda, Pfizer, GSK, Stemline Therapeutics, and Oncopeptides; and has a consultancy role for Sanofi; LG none; WR none; PT has received honoraria from Janssen, BMS\/Celgene, GlaxoSmithKline, Takeda, Amgen, Sanofi, Pfizer, AbbVie, and received support for traveling from Janssen, BMS\/Celgene, Sanofi and AMGEN; K.M. has received honoraria from Sanofi, Amgen, Janssen, GlaxoSmithKline, Pfizer, Bristol Myers Squibb and Oncopeptides; TS none; JC has received research funding from Janssen, and received honoraria from AMGEN and Janssen, and has received support for travel from GILEAD; SZ has received research funding from Takeda and Janssen, and serves in advisory boards for Janssen, Takeda, and BMS, all paid to institution; RH has received research funding from Janssen, AMGEN, Celgene\/BMS, Novartis, and Takeda, all paid to employer; and has received consulting fees from Janssen, AMGEN, Celgene, Abbvie, BMS, Novartis, Pharmamar, and Takeda; and has received honoraria from Janssen, AMGEN, Celgene, BMS, Pharmamar, and Takeda; and has received support for attending meetings from AMGEN, Celgene, Takeda, and Janssen; and has participated on advisory boards from BMS, Takeda, AMGEN, Oncopeptides, Sanofi, Janssen, and GSK; RB has received an educational grant from BMS\/Celgene; A.J.V. has received honoraria from BMS; MB has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, BMS, and Mundipharma, and honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, BMS, and Abbvie, and served in advisory boards for Janssen; FG has received honoraria from Amgen, Celgene, Janssen, Takeda, Bristol Myers Squibb, AbbVie, GlaxoSmithKline, and participates on data safety monitoring board or advisory board of Amgen, Celgene, Janssen, Takeda, Bristol Myers Squibb, AbbVie, GlaxoSmithKline, Roche, Adaptive Biotechnologies, Oncopeptides, bluebird bio, and Pfizer; PS serves in advisory boards from Amgen, BMS, Celgene, Janssen, Karyopharm, and Pfizer, and receives research funding from Amgen, BMS, Celgene, Janssen, Karyopharm, and Pfizer; PM has received honoraria from and\/or served on advisory boards for Abbvie, Alexion, Amgen, Astellas, Astra-Zeneca, Bei-Gene, Bristol-Myers Squibb, Daichi-Sankyo, Eli-Lilly, Gilead, Glaxo-Smith-Kline, Grifols, Incyte, Johnson & Johnson, Jazz, Kyowa Kirin, Menarini-Stemline, Otsuka, Novartis, Pfizer, Roche, Sanofi, Servier, Sobi, and Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}